SummaryTESSALON® (Benzonatate) is an FDA-approved non-narcotic oral antitussive medication manufactured by Pfizer Inc. It was first approved in the United States in 1958 for the symptomatic relief of cough. TESSALON acts as a sodium channel blocker, anesthetizing the stretch receptors in the respiratory passages, lungs, and pleura to dampen their activity and reduce the cough reflex. Its effect starts within 15-20 minutes and can last between 3-8 hours. TESSALON has no inhibitory effect on the respiratory center when used as recommended. The active ingredient, 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate, has a molecular weight of 603.7. TESSALON is solely indicated for the relief of cough, but it has no known potential for abuse or addiction, unlike narcotic antitussives. |
Drug Type Small molecule drug |
Synonyms 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl p-(butylamino)benzoate, 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate, 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate + [8] |
Target |
Mechanism SCNA blockers(Sodium channel alpha subunit blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (10 Feb 1958), |
Regulation- |
Molecular FormulaC30H53NO11 |
InChIKeyMAFMQEKGGFWBAB-UHFFFAOYSA-N |
CAS Registry104-31-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00242 | Benzonatate |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Cough | US | 10 Feb 1958 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Dry cough | Phase 3 | IN | 26 Jan 2011 |